Jessica L Lo Surdo1, Bryan A Millis, Steven R Bauer. 1. FDA/Center for Biologics Evaluation and Research, Division of Cellular and Gene Therapies, Office of Cellular, Tissue, and Gene Therapies, Bethesda, Maryland, USA.
Abstract
BACKGROUND AIMS: Multipotent stromal cells, also called mesenchymal stromal cells (MSCs), are potentially valuable as a cellular therapy because of their differentiation and immunosuppressive properties. As the result of extensive heterogeneity of MSCs, quantitative approaches to measure differentiation capacity between donors and passages on a per-cell basis are needed. METHODS: Human bone marrow-derived MSCs were expanded to passages P3, P5 and P7 from eight different donors and were analyzed for colony-forming unit capacity (CFU), cell size, surface marker expression and forward/side-scatter analysis by flow cytometry. Adipogenic differentiation potential was quantified with the use of automated microscopy. Percentage of adipogenesis was determined by quantifying nuclei and Nile red-positive adipocytes after automated image acquisition. RESULTS: MSCs varied in expansion capacity and increased in average cell diameter with passage. CFU capacity decreased with passage and varied among cell lines within the same passage. The number of adipogenic precursors varied between cell lines, ranging from 0.5% to 13.6% differentiation at P3. Adipogenic capacity decreased significantly with increasing passage. MSC cell surface marker analysis revealed no changes caused by passaging or donor differences. CONCLUSIONS: We measured adipogenic differentiation on a per-cell basis with high precision and accuracy with the use of automated fluorescence microscopy. We correlated these findings with other quantitative bioassays to better understand the role of donor variability and passaging on CFU, cell size and adipogenic differentiation capacity in vitro. These quantitative approaches provide valuable tools to measure MSC quality and measure functional biological differences between donors and cell passages that are not revealed by conventional MSC cell surface marker analysis. Published by Elsevier Inc.
BACKGROUND AIMS: Multipotent stromal cells, also called mesenchymal stromal cells (MSCs), are potentially valuable as a cellular therapy because of their differentiation and immunosuppressive properties. As the result of extensive heterogeneity of MSCs, quantitative approaches to measure differentiation capacity between donors and passages on a per-cell basis are needed. METHODS:Human bone marrow-derived MSCs were expanded to passages P3, P5 and P7 from eight different donors and were analyzed for colony-forming unit capacity (CFU), cell size, surface marker expression and forward/side-scatter analysis by flow cytometry. Adipogenic differentiation potential was quantified with the use of automated microscopy. Percentage of adipogenesis was determined by quantifying nuclei and Nile red-positive adipocytes after automated image acquisition. RESULTS: MSCs varied in expansion capacity and increased in average cell diameter with passage. CFU capacity decreased with passage and varied among cell lines within the same passage. The number of adipogenic precursors varied between cell lines, ranging from 0.5% to 13.6% differentiation at P3. Adipogenic capacity decreased significantly with increasing passage. MSC cell surface marker analysis revealed no changes caused by passaging or donor differences. CONCLUSIONS: We measured adipogenic differentiation on a per-cell basis with high precision and accuracy with the use of automated fluorescence microscopy. We correlated these findings with other quantitative bioassays to better understand the role of donor variability and passaging on CFU, cell size and adipogenic differentiation capacity in vitro. These quantitative approaches provide valuable tools to measure MSC quality and measure functional biological differences between donors and cell passages that are not revealed by conventional MSC cell surface marker analysis. Published by Elsevier Inc.
Entities:
Keywords:
adipogenesis; bone marrow stromal cell; mesenchymal stromal cell; microscopy
Authors: P J Psaltis; S Paton; F See; A Arthur; S Martin; S Itescu; S G Worthley; S Gronthos; A C W Zannettino Journal: J Cell Physiol Date: 2010-05 Impact factor: 6.384
Authors: E Donzelli; A Salvadè; P Mimo; M Viganò; M Morrone; R Papagna; F Carini; A Zaopo; M Miloso; M Baldoni; G Tredici Journal: Arch Oral Biol Date: 2006-10-16 Impact factor: 2.633
Authors: Evelyn Kendall Williams; José R García; Robert G Mannino; Rebecca S Schneider; Wilbur A Lam; Andrés J García Journal: Integr Biol (Camb) Date: 2019-04-01 Impact factor: 2.192
Authors: Warren L Grayson; Bruce A Bunnell; Elizabeth Martin; Trivia Frazier; Ben P Hung; Jeffrey M Gimble Journal: Nat Rev Endocrinol Date: 2015-01-06 Impact factor: 43.330
Authors: Matthew W Klinker; Ross A Marklein; Jessica L Lo Surdo; Cheng-Hong Wei; Steven R Bauer Journal: Proc Natl Acad Sci U S A Date: 2017-03-10 Impact factor: 11.205
Authors: Johnny Lam; Ross A Marklein; Jose A Jimenez-Torres; David J Beebe; Steven R Bauer; Kyung E Sung Journal: SLAS Technol Date: 2017-08-21 Impact factor: 3.047
Authors: Brian G Stultz; Kathleen McGinnis; Elaine E Thompson; Jessica L Lo Surdo; Steven R Bauer; Deborah A Hursh Journal: Cytotherapy Date: 2016-01-15 Impact factor: 5.414
Authors: Matthew J Thompson; Gaurangkumar Patel; Jonathan Isaacs; John McMurtry; Nathan Richards; William Daner Journal: Neurol Res Date: 2017-01-23 Impact factor: 2.448
Authors: Maha A Qadan; Nicolas S Piuzzi; Cynthia Boehm; Wesley Bova; Malcolm Moos; Ronald J Midura; Vincent C Hascall; Christopher Malcuit; George F Muschler Journal: Cytotherapy Date: 2018-02-01 Impact factor: 5.414
Authors: Yazmin I Rovira Gonzalez; Patrick J Lynch; Elaine E Thompson; Brian G Stultz; Deborah A Hursh Journal: Cytotherapy Date: 2016-07-12 Impact factor: 5.414
Authors: Michael J Rutten; Bryan Laraway; Cynthia R Gregory; Hua Xie; Christian Renken; Charles Keese; Kenton W Gregory Journal: Stem Cell Res Ther Date: 2015-10-05 Impact factor: 6.832